SynthesisBlood advances2026
Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis.
Synthesis in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe optimal anticoagulant strategy for portal vein thrombosis (PVT) in patients with cirrhosis remains uncertain, particularly regarding the role of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs), low-molecular-weight heparin, or no anticoagulation. We conducted a systematic review and meta-analysis of studies evaluating DOAC therapy in patients with cirrhosis with PVT. Random-effects models were used to estimate pooled risk ratios (RRs). A total of 21 studies including 21 506 patients with cirrhosis with PVT were analyzed. Among them, 2099 patients were treated with DOACs. Compared with VKAs, DOAC therapy was associated with higher rates of complete PVT recanalization (RR, 3.49; 95% confidence interval [CI], 2.06-5.93) and lower risk of PVT progression (RR, 0.19; 95% CI, 0.04-0.78), with no significant difference in major bleeding (RR, 1.09; 95% CI, 0.79-1.51). DOACs were also associated with a lower risk of intracranial hemorrhage (ICH; RR, 0.49; 95% CI, 0.30-0.80). Compared with no anticoagulation, DOAC therapy was associated with lower mortality (RR, 0.77; 95% CI, 0.71-0.84) without increased bleeding risk. DOAC benefit on recanalization was more pronounced in studies including only patients with Child-Pugh class A or B, whereas safety outcomes remained consistent across cirrhosis severity strata. In patients with cirrhosis with PVT, DOAC therapy is associated with improved complete recanalization and reduced PVT progression compared with VKAs, without increased bleeding risk and with lower risk of ICH. These findings support the use of DOACs in select patients, although randomized trials are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.